The Swiss pharma giant Roche announced yesterday that the first approved gene therapy for the treatment of Duchenne muscular dystrophy (DMD), Elevidys, demonstrated statistically significant ...

DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development ...

Scorpius BioManufacturing officials on Thursday told The Mercury the original deal they made with the state to construct a $650-million, 500,000-square-foot vaccine and biologic medicine plant is off ...

Scorpius BioManufacturing officials on Thursday told The Mercury the original deal they made with the state to construct a $650-million, 500,000-square-foot vaccine and biologic medicine plant is ...

“This collaboration reinforces Scorpius’ reputation as a trusted and innovative biomanufacturing partner,” said Jeff Wolf, CEO of Scorpius. “ErythroMer™ is a groundbreaking advancement that addresses ...

"This collaboration reinforces Scorpius' reputation as a trusted and innovative biomanufacturing partner," said Jeff Wolf, CEO of Scorpius. "ErythroMer is a groundbreaking advancement that ...

“This collaboration reinforces Scorpius’ reputation as a trusted and innovative biomanufacturing partner,” said Jeff Wolf, CEO of Scorpius. “ErythroMer™ is a ...

Both companies are also exploring a potential commercial-scale manufacturing agreement, reinforcing Scorpius's role as a reliable biomanufacturing partner. KaloCyte is advancing towards clinical ...

“This collaboration reinforces Scorpius’ reputation as a trusted and innovative biomanufacturing partner,” said Jeff Wolf, CEO of Scorpius. “ErythroMer™ is a groundbreaking advancement ...